You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A microfluidic device for blood analysis in neonates
SBC: Sersense Inc Topic: NICHDABSTRACT Premature infants are frequently at risk of infectionjaundice and hypoglycemiaconditions monitored by analysis of blood for c reactive proteinCRPbilirubin and glucose respectivelyTypicallymL of blood is drawn each time an infant is tested with multiple blood draws happening over the course of daysGiven that total blood volume of in premature infants ismLup toof blood volume may be lost du ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction
SBC: Renova Therapeutics, Inc. Topic: NHLBIABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complications and adverse cardiovascular eventsInsulin therapy is essential for such patientsbut has shortcomingsaonlyinpatients achieve targeted glucose controlHbA c andltbaggressive insulin therapy increases ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinoma
SBC: Avenzoar Pharmaceuticals, Inc. Topic: 102ABSTRACT Pancreatic cancer is a disease with no effective treatmentIt s low five year survival rateestimated at betweenandranks it the fourth highest of cancer related of death in the U Sdespite being the twelfth most common type of cancerEach year in the U Sthere are nearlynew cases and more thandeaths caused by the diseaseBypancreatic cancer is expected to be the second most common cancer relate ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel mobile application to assist in the diagnosis of Fetal Alcohol Syndrome (FAS)
SBC: Blue Resonance, LLC Topic: 270Project Summary AbstractFetal alcohol spectrum disorderFASDis a major public health issue resulting from prenatal alcohol exposurePAEimpacting betweenof the US population and perhaps more thanchildren globally each yearWhen assessing for FASD the following facial features must to be evaluated as part of the diagnostic processpalpebral fissure lengthPFLthinness of the upper vermillionand the smooth ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Oncolytic virus-mediated target delivery of a therapeutic antibody fragment in glioblastoma
SBC: Oncosynergy, Inc. Topic: 102PROJECT SUMMARY More thanpatients are diagnosed each year with glioblastomathe most common primary brain tumorCurrent treatments are inadequate and there have been no major therapeutic breakthroughs in decadesHencethere is an urgent need to develop novel strategies to address this devastating diseaseHoweverdevelopment of an effective treatment for glioblastoma is severely hampered bythe blood brai ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
LystaMab Immunotherapy to Inhibit Pericardial Adhesions
SBC: LYST THERAPEUTICS LLC Topic: NHLBISUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Translating an In-Person Brief, Bystander Bullying Intervention (STAC) to a Technology-Based
SBC: KLEIN BUENDEL, INC. Topic: 102Project Summary While studies support the efficacy of comprehensiveschool wide interventions in reducing bullyingthese types of programs can require significant time and financial resources for implementationresulting in barriers to providing school based bullying preventionespecially in low income and rural communitiesAdditionallyalthough training bystanders to act asdefenderson behalf of targets ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A Novel Two-in-One Approach to Administer Surfactant and Provide Airway Support to VLBW Infants
SBC: BB MEDICAL SURGICAL, INC. Topic: NICHDPROJECT SUMMARY / ABSTRACT Every year, 50,000 very low birth weight (VLBW, andlt;1,500 g) infants are born in the U.S. The use of surfactant dramatically decreases morbidity and mortality due to respiratory distress syndrome (RDS) in VLBW infants. Current standards for surfactant administration require the infant to be intubated, so that surfactant can be delivered to the trachea and lungs. Intuba ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.
SBC: Vova Ida, LLC Topic: 999SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Biosensor and Eyedrop Bottle Technologies for Glaucoma Adherence Monitoring
SBC: Toromedes, Inc Topic: NEIProject SummaryNon adherence with prescribed systemic drugs leads to poor outcomes and increases the cost of healthcareGlaucomathe leading cause of irreversible blindnessaffects more thanmillion people worldwideLowering intraocular pressurethe only proven method of delaying both the development and progression of glaucomais typically done with topical administration of eye dropswhich has notorious ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health